Bioinformatic Analysis Reveals VEGFA Promotes the Occurrence of PLA2R-associated Idiopathic Membranous Nephropathy by Angiogenesis via PI3K/AKT Signaling Pathway

Ben Ke (keben-1989125@163.com)
Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang of Jiangxi, 330006, China  https://orcid.org/0000-0002-4813-7108

Wen Shen
The Second Affiliated Hospital of Nanchang University

Zhibing Duan
The Second Affiliated Hospital of Nanchang University

Research

Keywords: VEGFA, PLA2R-associated idiopathic membranous nephropathy, PI3K/AKT signaling, SNARE proteins

DOI: https://doi.org/10.21203/rs.3.rs-76655/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: PLA2R-associated IMN covers 70% of IMN, which is one of the main types of chronic kidney disease in adults and one of the most common causes of end-stage renal disease. Vascular endothelial growth factor A (VEGFA), a homodimeric vasoactive glycoprotein, is the key mediator of angiogenesis, which lead to numerous kidney diseases, including TSHD7A-associated IMN. However, the role of VEGFA in PLA2R-associated IMN is still poorly understood.

Methods: We downloaded the microarray data GSE115857 from GEO. The DEGs were identified with R software, and the functional and pathway enrichment analysis of DEGs was performed utilizing the DAVID and Cytoscape ClueGo plug-in. A comprehensive list of interacting DEGs was constructed using the STRING database and visualized by Cytoscape software. The Cytoscape MCODE and cytoHubba plug-in were used to identify clustered sub-networks, and hub genes from the protein-protein interaction network. Gene set enrichment analysis (GSEA) was used to identify signaling pathway in IMN.

Results: There were 1422 genes (952 up-regulated genes and 470 down-regulated genes) were identified as DEGs in GSE115857. The BP of DEGs in GSE115857 was clustered in regulation of transcription from RNA polymerase II promoter, positive regulation of nuclear-transcribed mRNA poly(A) tail shortening, cell adhesion et al. The KEGG pathway of DEGs in GSE115857 was clustered in Rheumatoid arthritis, ABC transporters, PI3K/AKT signaling pathway et al. Then we got a huge PPI network from STRING. 6 modules were screen out to study the functional changes in IMN. The KEGG pathway of module 3 was enriched in soluble N-ethylmaleimide–sensitive factor attachment protein receptor (SNARE) interactions in vesicular transport. There were 3 hub genes screened out, namely, VEGFA, JUN, and FOS. Following the random walk, all genes were ranked and GSEA analysis showed that the signaling pathway of DEGs in GSE115857 was focused on angiogenesis, in which VEGFA acts as a core gene.

Conclusion: In summary, this study reveals VEGFA promotes PLA2R-associated IMN by stimulating angiogenesis via PI3K/AKT signaling. Moreover, SNARE interactions in vesicular transport was involved in the development of PLA2R-associated IMN, which may offer a novel therapeutic strategy in treatment of IMN.

Background

Membranous nephropathy (MN) is one of the most common causes of nephritic syndrome in adults and is the second commonest glomerulopathy to progress to end stage renal disease (ESRD). Most cases are idiopathic (IMN), but ~ 20% are secondary to various causes, including cancers, infections, autoimmune diseases, and medications [1]. The M-type phospholipase A2 receptor (PLA2R) and thrombospondin type1 domain-containing 7A (TSHD7A) are two major autoantigens against podocyte antigens in idiopathic membranous nephropathy (IMN) [2, 3]. PLA2R-associated IMN is a primary membranous nephropathy with positive serum anti-PLA2R antibody, which covers 70% of IMN [2]. The characteristic feature of IMN is immune complex (IC) formation/deposition on the sub-epithelial side of the glomerular
basement membrane resulting in podocyte injury, in which membrane attack complex C5b-9 induces a variety of downstream pathways, including protein kinases, lipid metabolism, reactive oxygen species, growth factors/gene transcription, endoplasmic reticulum stress, and the ubiquitin-proteasome system [4].

The vascular endothelial growth factor A (VEGFA), a homodimeric vasoactive glycoprotein, is the key mediator of angiogenesis. Angiogenesis, the formation of new blood vessels, is responsible for a wide variety of physio/pathological processes in kidney diseases, such as diabetic kidney disease, and polycystic kidney disease [5]. In the renal glomeruli, VEGFA is mainly expressed in and secreted from podocytes and tubular epithelial cells, which induces renal injury through binding to receptor VEGFR, mainly VEGFR2, which expressed on the surface of endothelial cells [6]. In recent decades, studies that investigated dysregulation of VEGFA expression during kidney diseases have led to the identification of a crucial role of this proangiogenic factor in the renal capillary network [7, 8]. Ayumi Matsumoto et al. reported that VEGFA may be important for TSHD7A-associated IMN pathogenesis [9]. However, the role of VEGFA in PLA2R-associated IMN is poorly studied.

The phosphoinositide 3-kinase (PI3K)/AKT signaling plays an important role in physiological and pathological conditions of the organism. In the present study, we attempted to identify crucial genes and pathways that are involved in the pathogenesis of PLA2R-associated IMN. We found that VEGFA is highly expressed in kidney tissue from PLA2R-associated IMN patients. VEGFA may promote the occurrence of PLA2R-associated IMN by stimulating angiogenesis via PI3K/AKT signaling. Moreover, we found six modules that closely related to the development of PLA2R-associated IMN. In addition, SNARE interactions in vesicular transport was involved in the occurrence and progression of PLA2R-associated IMN, which has not been reported before. These results may provide new targets for the treatment of IMN.

Methods

Microarray data information

We used “membranous nephropathy” as the keyword to search the Gene Expression Omnibus (GEO) database. We selected the expression profiling of the array: the attribute name was tissue, and the organisms were Homo sapiens, and only the array with high expression of M-type phospholipase A2 receptor 1 (PLA2R1) was chosen to further analysis (Accession number: GSE115857). GSE115857 contains 11 renal biopsys from IMN patients, and 7 renal biopsys from living donors, which is based on the GPL14951 (Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip) platform.

Because the data in this experiment were all from public databases, there was no need for approval by the ethics committee.

Identification of differentially expressed genes
The R software (Version 3.6.2) was utilized to screen differentially expressed genes (DEGs) between the IMN group and living donors group. An adjusted p-value of <0.05 and |logFC| >1.0 were considered statistically significant. The ggplot2 and RColorBrewer package in R was used to plot the volcano map and the heat map in the two groups.

**Gene ontology and pathway enrichment analysis**

Gene Ontology (GO) includes three categories: molecular function (MF), biological process (BP), and cellular component (CC). GO and KEGG pathway analysis were performed via Database for annotation, Visualization and Integrated Discovery (DAVID) [10] and Cytoscape ClueGo plug-in. Gene Set Enrichment Analysis (GSEA) determines whether an a priori defined set of genes has statistically significant differences in expression under two different biological conditions [11]. This analysis, performed using GSEA software 4.0.3 from the Broad Institute. The gene set of “h.all.v7.1.symbols.gmt”, which summarizes and represents specific, well-defined biological states or processes, was downloaded from the Molecular Signatures Database (http://software.broadinstitute.org/gsea/msigdb/index.jsp). The normalized enrichment score (NES) was determined by analysis of 1000 permutations. A gene set was considered significantly enriched when the P-value was less than 0.05 and the false discovery rate (FDR) was less than 0.25.

**Protein–protein interaction network and hub gene identification**

To evaluate the interactive relationships among DEGs, the STRING online database (https://string-db.org) was used [12]. The protein–protein interaction (PPI) network of DEGs was visualized with Cytoscape software, and central genes were identified by cytoHubba to select the hub genes, which were intersected by Betweenness, Bottleneck, Closeness, and Degree method [13]. Significant modules in the PPI network were identified by Molecular Complex Detection (MCODE), a plug-in of Cytoscape software that clusters a network based on topology to recognize closely connected regions [14]. The MCODE algorithm sorts and identifies each identified module. The higher the score, the stronger the genes association in this module. The parameters of DEGs clustering and scoring were set as follows: MCODE score ≥4, degree cutoff =2, node score cut-off=0.2, max depth=100 and k-score=4. Pathway, and BP enrichment analysis was performed for DEGs in the identified modules using ClueGo, a plug-in of Cytoscape software.

**Results**

**Identification of DEGs**

A total of 1422 DEGs were identified in GSE73953, including 952 up-regulated genes and 470 down-regulated genes. The volcano plot of all DEGs and heat map of the top 50 up-regulated genes and the top 50 down-regulated genes are shown in Figures 1 and 2, respectively.

**Pathway and GO enrichment analysis of DEGs**
GO enrichment and KEGG pathway analysis was performed with DAVID, which consists of three terms, as shown in Figure 3(a), (b), (c), and (d).

The top 15 biological process (BP) of DEGs in GSE115857 was clustered in regulation of transcription from RNA polymerase II promoter (GO:0006357, 54DEGs), positive regulation of nuclear-transcribed mRNA poly(A) tail shortening (GO:0060213, 7DEGs), cell adhesion (GO:0007155, 48DEGs), positive regulation of nuclear-transcribed mRNA catabolic process, deoxyribonucleoside triphosphate-dependent decay (GO:1900153, 6DEGs), response to cytokine (GO:0034097,11DEGs), extracellular matrix organization (GO:0030198,25DEGs), signal transduction (GO:0007165,99DEGs), cellular response to fibroblast growth factor stimulus (GO:0044344, 8DEGs), cell migration (GO:0016477,22DEGs), positive regulation of I-kappa B kinase/NF-kappa B signaling (GO:0043123,21DEGs), response to drug (GO:0042493,33DEGs), response to organic cyclic compound (GO:0014070,10DEGs), response to mechanical stimulus (GO:0009612,11DEGs), positive regulation of positive chemotaxis (GO:0050927,5DEGs), and negative regulation of cell proliferation (GO:0008285,40DEGs) (Table 1).

The top 15 cellular component (CC) of DEGs in GSE115857 was clustered in postsynaptic density (GO:0014069,27DEGs), cytosol (GO:0005829,246DEGs), nucleus (GO:0005634,380DEGs), nucleoplasm (GO:0005654,207DEGs), endoplasmic reticulum (GO:0005783,72DEGs), focal adhesion (GO:0005925,37DEGs), membrane (GO:0016020,160DEGs), CCR4-NOT complex (GO:0030014,5DEGs), SNARE complex (GO:0031201,9DEGs), cell projection (GO:0042995,11DEGs), nuclear membrane (GO:0031965,23DEGs), mitochondrion (GO:0005739,99DEGs), extracellular space (GO:0005615,100DEGs), phagocytic vesicle (GO:0045335,7DEGs), intracellular (GO:0005622,98DEGs), and mast cell granule (GO:0042629,5DEGs).

The top 15 molecular function (MF) of DEGs in GSE115857 was clustered in protein binding (GO:0005515,620DEGs), transcription factor activity, sequence-specific DNA binding (GO:0003700,92DEGs), identical protein binding (GO:0042802,68DEGs), neurotrophin TRKA receptor binding (GO:0005168,4DEGs), ATPase activity, coupled to transmembrane movement of substances (GO:0042626,9DEGs), steroid hormone receptor activity (GO:0003707,10DEGs), sequence-specific DNA binding (GO:0043565,47DEGs), transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding (GO:0000982,6DEGs), transcription factor binding (GO:0008134,29DEGs), zinc ion binding (GO:0008270,93DEGs), syntaxin-1 binding (GO:0017075,5DEGs), palmitoyl-CoA hydrolase activity (GO:0016290,4DEGs), anion transmembrane-transporting ATPase activity (GO:0043225,4DEGs), RNA polymerase II activating transcription factor binding (GO:0001102,7DEGs), and beta-catenin binding (GO:0008013,11DEGs).

The top 15 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of DEGs in GSE115857 was clustered in Rheumatoid arthritis (hsa05323,15DEGs), ABC transporters (hsa02010,10DEGs), TNF signaling pathway (hsa04668,16DEGs), SNARE interactions in vesicular transport (hsa04130,8DEGs), HTLV-I infection (hsa05166,28DEGs), Ubiquitin mediated proteolysis (hsa04120,17DEGs), Salmonella infection (hsa05132,12DEGs), Cell adhesion molecules (CAMs) (hsa04514,17DEGs), Osteoclast.
differentiation (hsa04380, 16DEGs), NF-kappa B signaling pathway (hsa04668, 12DEGs), PI3K-Akt signaling pathway (hsa04152, 14DEGs), ECM-receptor interaction (hsa04512, 11DEGs), AMPK signaling pathway (hsa04512, 14DEGs), Amphetamine addiction (hsa05031, 9DEGs), and Chagas disease (American trypanosomiasis) (hsa05142, 12DEGs) (Table 2).

**PPI network and hub gene analysis**

To explore the relationship between these DEGs and to identify hub genes, a PPI network of DEGs was constructed using the STRING online database and visualized using Cytoscape. There were 1199 nodes and 5490 edges in the PPI network, including 760 up-regulated genes, 350 down-regulated genes. In addition, 6 modules from the PPI network were selected using the MCODE plug-in of Cytoscape: module 1 (score=24), consisting of 24 nodes and 276 edges (Figure 4 (a)), module 2 (score=13.04), consisting of 26 nodes and 163 edges (Figure 4 (b)), module 3 (score=8.078), consisting of 52 nodes and 206 edges (Figure 4 (c)), module 4 (score=5.971), consisting of 71 nodes and 209 edges (Figure 4 (d)), module 5 (score=5.051), consisting of 60 nodes and 149 edges (Figure 4 (e)), module 6 (score=4.654), consisting of 53 nodes and 121 edges (Figure 4(f)). Then, GO and pathway enrichment analysis of these module genes were performed by CluGo plug-in of Cytoscape.

For the BP, genes from module 1 were most significantly clustered in positive regulation of mitotic metaphase/anaphase transition (GO:0045842, 5DEGs), there is no BP enrichment in module 2, genes from module 3 were most significantly clustered in organelle fusion (GO:0048284, 15DEGs) and regulation of glomerular filtration (GO:0003093, 4DEGs), genes from module 4 were most significantly clustered in ribonucleoprotein complex export from nucleus (GO:0071426, 10DEGs), genes from module 5 were most significantly clustered in cell adhesion mediated by integrin (GO:0033627, 8DEGs) and maturation small subunit ribosomal RNA (SSU-rRNA) (GO:0030490, 6DEGs), genes from module 6 were most significantly clustered in pentose-phosphate shunt, oxidative branch (GO:0009051, 4DEGs) (Figure 5, Table 3).

For CC, genes from module 1 were most significantly clustered in cullin-RING ubiquitin ligase complex (GO:0031461, 12DEGs), genes from module 2 were most significantly clustered in clathrin-coated vesicle (GO:00300136, 13DEGs), genes from module 3 were most significantly clustered in SNARE complex (GO:0031201, 9DEGs), specific granule (GO:0042581, 15DEGs), phagocytic vesicle (GO:0045335, 11DEGs), and mast cell granule (GO:0042629, 4DEGs) (Figure 6).

For MF, there is no MF enrichment in module 1, genes from module 2 were most significantly clustered in clathrin adaptor activity (GO:0035615, 3DEGs), genes from module 3 were most significantly clustered in SNAP receptor activity (GO:0005484, 7DEGs), glucocorticoid receptor binding (GO:0035259, 3DEGs ), and thrombin-activated receptor activity (GO:0015057, 3DEGs ), genes from module 4 were most significantly clustered in extracellular matrix structural constituent conferring tensile strength (GO:0030020, 5DEGs), genes from module 6 were most significantly clustered in phosphatidate phosphatase activity (GO:0008195, 3DEGs) (Figure 7).
For KEGG enrichment, genes from module 1 were clustered in ubiquitin mediated proteolysis (KEGG:04120, 15DEGs), genes from module 3 were clustered in soluble NSF Attachment Protein Receptor (SNARE) interactions in vesicular transport (KEGG:04130, 8DEGs), genes from module 4 were clustered in extracellular matrix (ECM)-receptor interaction (KEGG:04512, 8DEGs), there is no KEGG enrichment in module 2, 5 and 6 (Figure 8, Table 4).

In the present study, we used cytoHubba to choose hub genes. According to the five classification methods in cytoHubba, the top 30 hub genes selected by these ranked methods in cytoHubba are shown in Table 5. Finally, three central genes were identified by overlapping the first 30 genes, as shown in Figure 9. VEGFA is the most excellent central genes based on five ranked methods. JUN and FOS were also selected as hub genes (Table 6).

**GSEA identifies signaling pathways in IMN**

We compared the data sets for IMN and living donors using GSEA to identify signaling pathways. The results indicated significant differences (FDR < 0.25, NOM P-value < 0.05) in the enrichment of the MSigDB collection (h.all.v7.1.symbols.gmt). We selected the most significantly enriched signaling pathways, based on normalized enrichment score (NES) (Figure 10, Table 7). The results indicated the data set with IMN was enriched for angiogenesis. 13 core genes were found, including PTK2, SLCO2A1, COL3A1, FSTL1, CCND2, SERPINA5, VEGFA, VAV2, OLR1, APP, POSTN, VCAN, and NRP1 (Figure 11).

**Discussion**

In recent years, with the use of vascular endothelial growth factor A (VEGFA) inhibitor in oncology, the number of patients with kidney disease is increasing, mainly manifested as thrombotic microangiopathy, minimal change nephropathy, and collapsing focal segmental glomerulosclerosis [8, 15, 16], however, there is no membrane nephropathy reported. Additionally, rituximab, a B cell-target monoclonal antibody, which has become the first line therapy in IMN according to KDIGO CLINICAL PRACTICE GUIDELINE ON GLOMERULAR DISEASES 2020, showed its ability to decrease the VEGFA level in plasma in patients with recurrent mantle cell lymphoma [17]. These data suggest that VEGFA may get involved in the development of MN. In this study, we identified 1422 genes as DEGs in kidney from IMN patients compared to living donors, 3 hub genes, one up-regulated gene VEGFA, two down-regulated genes JUN and FOS, and six significant modules selected from a PPI network, which partially revealed the molecular mechanism in IMN and may be used to develop novel targets for IMN treatment. Moreover, we found that soluble N-ethylmaleimide–sensitive factor attachment protein receptor (SNARE) interactions in vesicular transport involved in the occurrence and progression of PLA2R-associated IMN, which was first reported in this paper.

Angiogenesis is a process of new blood vessel formation from existing vessels, which are essential for the formation of normal kidney structures and for the functions of glomeruli [18]. Abnormal capillary formation in the kidney may cause morphological changes in glomeruli, as well as infiltration of inflammatory cells [19]. Angiogenesis is tightly regulated by a balance of proangiogenic and
antiangiogenic factors, in which the most potent proangiogenic factor, vascular endothelial growth factor A (VEGFA), has been intensively investigated \[15\]. VEGFA is the predominant isoform of VEGF in humans and one of the most potent proangiogenic factors, which is mainly expressed in and secreted from podocytes \[7\] and renal tubular epithelial cells in glomeruli \[5\]. Expression of VEGFA promotes endothelial cell proliferation, migration, and survival, but can also be associated with vascular hyperpermeability in inflammatory conditions including inflammatory kidney diseases via binding to receptor VEGFR2 \[20\]. Neuropilin 1 (NRP1) functions as a co-receptor for VEGFA and is required for complete activation of VEGFR2 \[21\]. As VEGFR2 is expressed on the surface of endothelial cells, VEGFA-mediated epithelial–endothelial crosstalk in the glomeruli plays an essential role in numerous renal injury \[22\]. In the present study, we found that VEGFA and NRP1 are highly expressed in kidney tissue from IMN patients. GSEA analysis confirmed that the up-regulated VEGFA promotes angiogenesis in IMN group. Pathway enrichment analysis found that the biological process induced by VEGFA is associated with PI3K/Akt signaling. In addition to, the biological process of modules 3 was clustered in cell migration involved in sprouting angiogenesis, which is a main type of angiogenesis. Thus, VEGFA activates PI3K/Akt signaling via binding to VEGFR2 to accelerate angiogenesis, and leads to vascular hyperpermeability, which result in increased filtration of inflammatory factors, complement, and cytokines, eventually lead to immune complex (IC) and MAC formation. These results suggest that regulation of the VEGFA/PI3K/Akt signalling pathway may be a treatment strategy for IMN.

Complement-mediated cell injury has been demonstrated to contribute to IMN \[4\]. With complement activation, the formation of membrane attack complex C5b-9 in plasma membranes on the soles of the foot processes of visceral glomerular epithelial cells, which has been shown to induce kidney cell injury through activating a variety of downstream pathways including focal adhesion kinases \[23\], lipid metabolism, reactive oxygen species, growth factors/gene transcription, endoplasmic reticulum stress, the ubiquitin-proteasome system \[4\] and DNA damage \[24\], and it impacts the integrity of the cytoskeleton and slit diaphragm proteins, and contributes to the pathogenesis of mesangial-proliferative glomerulonephritis, thrombotic microangiopathy, and acute kidney injury \[4\]. In our study, six modules were found from PPI network. Our finding remains consistent with previous studies. The biological process of genes from six modules were clustered in positive regulation of mitotic metaphase/anaphase transition, regulation of glomerular filtration, cell adhesion mediated by integrin, pentose-phosphate shunt, oxidative branch, intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress, nucleotide-excision repair, DNA incision, and fatty acid metabolism. The KEGG pathway enrichment was clustered in ubiquitin mediated proteolysis, and ECM-receptor interaction. Thus, it seems that the vascular hyperpermeability induced by VEGFA/PI3K/Akt signalling plays an initial role in the development of IMN (Figure 12).

Notably, we found that SNARE interactions in vesicular transport was involved in the development of IMN, which was the first reported in this paper. Soluble Nethylmaleimide–sensitive factor attachment protein receptor (SNARE) proteins are essential for exocytosis, mediating the fusion of vesicles with their target membrane. Study reported that SNARE proteins mediate fusion of autophagosomes with endolysosomal vesicles, which mediates autophagosome maturation, resulting in autophagy \[25\]. And inhibiting
autophagosomes induced excessive autophagy ameliorates proteinuria and protect against glomerular and podocyte injury in nephrotic syndrome rats [26]. Moreover, with accumulation of autophagosomes, cell viability altered, which directly induces cellular toxicity [27]. In our report, we found that genes, including STX6, STX3, VAMP1, VAMP3, VAMP4, STX1B, and SEC22B, encoding SNARE proteins are highly expressed in kidney biopsies from IMN patients, which means inhibitor of SNARE interaction may provide a new therapeutic strategy in treating IMN, however, it needs to be verified experimentally.

It should be noted that there were some limitations to our research. First, recent study demonstrated that there are three non-HLA loci, namely, NFKB1, IRF4 and PLA2R1 revealed in IMN, which means that the canonical NF-κB pathway plays an active role in IMN [28], however, there is no significantly different expression of NFKB1 and IRF4 in this study. The shortage may be that the samples from these two groups are too small. Second, focusing on validated target genes may exclude potential targets that have not been validated by the experiment. Finally, due to its descriptive nature, we were not able to validate our hypothesis in this study.

**Conclusion**

The present study suggests that the PI3K-Akt signaling pathway is involved in the pathogenesis of IMN. VEGFA overexpressed in IMN, and is an important therapeutic target for IMN, which may lead to vascular hyperpermeability via PI3K-Akt signaling pathway, resulting in increased filtration of inflammatory factors, complement, and cytokines, eventually contribute to immune complex (IC) and MAC formation in IMN. Moreover, SNARE interactions in vesicular transport involved in the development of IMN, which needs further basic studies to validate our results and to illuminate the molecular mechanism in IMN.

**Abbreviations**
| Abbreviation | Full Form |
|--------------|-----------|
| PLA2R        | The M-type phospholipase A2 receptor |
| IMN          | Idiopathic membranous nephropathy |
| VEGFA        | Vascular endothelial growth factor A |
| VEGFR2       | Vascular endothelial growth factor receptor 2 |
| GEO          | Gene Expression Omnibus |
| DEGs         | Differentially expressed genes |
| DAVID        | Database for annotation, Visualization and Integrated Discovery |
| STRING       | Search Tool for the Retrieval of Interacting Genes |
| GSEA         | Gene set enrichment analysis |
| GO           | Gene Ontology |
| BP           | Biological process |
| CC           | Cellular component |
| MF           | Molecular function |
| KEGG         | Kyoto Encyclopedia of Genes and Genomes |
| MCODE        | Molecular Complex Detection |
| SNARE        | Soluble N-ethylmaleimide–sensitive factor attachment protein receptor |
| ECM          | Extracellular matrix |
| SSU-rRNA     | Small subunit ribosomal RNA |
| PI3K         | Phosphoinositide 3-kinase |
| NES          | Normalized enrichment score |
| FDR          | False discovery rate |
| PPI          | Protein–protein interaction |
| CAMs         | Cell adhesion molecules |
| AMPK         | Adenosine 5’-monophosphate (AMP)-activated protein kinase |
| KDIGO        | Kidney Disease | Improving Global Outcomes |
| NRP1         | Neuropilin 1 |
| IC           | Immune complex |
| MAC          | Membrane attack complex |
| NFKB1        | Nuclear factor kappa B 1 |
Declarations

Acknowledgements

Not applicable.

Funding

This work was supported by grants from the National Natural Science Foundation of China (General Program 81860133).

Author information

Affiliations

Department of Nephrology, The Second Affiliated Hospital of Nanchang University, China

Ben Ke & Zhibing Duan

Department of Cardiovascular Medicine, The Second Affiliated Hospital to Nanchang University, China

Wen Shen

Contributions

Ben Ke and Wen Shen outlined the manuscript, conceived the project and wrote the manuscript. Ben Ke designed and performed data analysis, drafted the manuscript with additional input from all authors and wrote the manuscript. Zhibing Duan designed and performed the data analysis. Ben Ke and Wen Shen performed the data analysis. Ben Ke and Zhibing Duan contributed to the literature search and data collection. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ben Ke

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.
Competing interests

The authors declare that they have no competing interests.

Availability of supporting data

Not applicable.

References

1. Filippone EJ: **Idiopathic membranous nephropathy and IgG4: an interesting relationship.** *Clin Nephrol* 2014, **82**:7-15.

2. Beck LH, Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: **M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.** *N Engl J Med* 2009, **361**:11-21.

3. Tomas NM, Beck LH, Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, et al: **Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.** *N Engl J Med* 2014, **371**:2277-2287.

4. Takano T, Elimam H, Cybulsky AV: **Complement-mediated cellular injury.** *Semin Nephrol* 2013, **33**:586-601.

5. Dimke H, Sparks MA, Thomson BR, Frische S, Coffman TM, Quaggin SE: **Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney.** *J Am Soc Nephrol* 2015, **26**:1027-1038.

6. Schrijvers BF, Flyvbjerg A, De Vriese AS: **The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.** *Kidney Int* 2004, **65**:2003-2017.

7. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: **Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.** *J Clin Invest* 2003, **111**:707-716.

8. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, et al: **VEGF inhibition and renal thrombotic microangiopathy.** *N Engl J Med* 2008, **358**:1129-1136.

9. Matsumoto A, Matsui I, Namba T, Sakaguchi Y, Mizuno H, Shirayama Y, Shimada K, Hashimoto N, Doi Y, Yamaguchi S, et al: **VEGF-A Links Angiolymphoid Hyperplasia With Eosinophilia (ALHE) to THSD7A Membranous Nephropathy: A Report of 2 Cases.** *Am J Kidney Dis* 2019, **73**:880-885.

10. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA: **DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists.** *Nucleic Acids Res* 2007, **35**:W169-175.

11. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: **Gene set enrichment analysis: a knowledge-based approach for...**
interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005, 102:15545-15550.

12. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, Jensen LJ: STRING v9.1: protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res* 2013, 41:D808-815.

13. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY: cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol* 2014, 8 Suppl 4:S11.

14. Bader GD, Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics* 2003, 4:2.

15. Tanabe K, Wada J, Sato Y: Targeting angiogenesis and lymphangiogenesis in kidney disease. *Nat Rev Nephrol* 2020, 16:289-303.

16. Estrada CC, Maldonado A, Mallipattu SK: Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. *J Am Soc Nephrol* 2019, 30:187-200.

17. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shklai M, Rabizadeh E: All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. *Leuk Res* 2004, 28:243-248.

18. Babickova J, Klinkhammer BM, Buhl EM, Djudjaj S, Hoss M, Heymann F, Tacke F, Floege J, Becker JU, Boor P: Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. *Kidney Int* 2017, 91:70-85.

19. Tanaka T, Nangaku M: Angiogenesis and hypoxia in the kidney. *Nat Rev Nephrol* 2013, 9:211-222.

20. Tanabe K, Maeshima Y, Sato Y, Wada J: Antiangiogenic Therapy for Diabetic Nephropathy. *Biomed Res Int* 2017, 2017:5724069.

21. Guo HF, Vander Kooi CW: Neuropilin Functions as an Essential Cell Surface Receptor. *J Biol Chem* 2015, 290:29120-29126.

22. Dimke H, Maezawa Y, Quaggin SE: Crosstalk in glomerular injury and repair. *Curr Opin Nephrol Hypertens* 2015, 24:231-238.

23. George B, Verma R, Soofi AA, Garg P, Zhang J, Park TJ, Giardino L, Ryzhova L, Johnstone DB, Wong H, et al: Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. *J Clin Invest* 2012, 122:674-692.

24. Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. *J Clin Invest* 2003, 111:877-885.

25. Zhao YG, Zhang H: Autophagosome maturation: An epic journey from the ER to lysosomes. *J Cell Biol* 2019, 218:757-770.

26. Yu ZK, Yang B, Zhang Y, Li LS, Zhao JN, Hao W: Modified Huangqi Chifeng decoction inhibits excessive autophagy to protect against Doxorubicin-induced nephrotic syndrome in rats via the PI3K/mTOR signaling pathway. *Exp Ther Med* 2018, 16:2490-2498.
27. Button RW, Roberts SL, Willis TL, Hanemann CO, Luo S: Accumulation of autophagosomes confers cytotoxicity. *J Biol Chem* 2017, 292:13599-13614.

28. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, Cui Z, Lin L, Hu X, Yu X, et al: The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. *Nat Commun* 2020, 11:1600.

Tables

Table 1 The top 15 biological process of DEGs
| Description                                                                 | P Value    | Count | Gene Symbol                                                                                           |
|----------------------------------------------------------------------------|------------|-------|-------------------------------------------------------------------------------------------------------|
| GO:0006357 regulation of transcription from RNA polymerase II promoter    | 4.80E-06   | 54    | FOSL2, MED24, MED23, FOXO3, FOS, ATP2B4, TRAK2, SMARC3, ZNF444, FOSL1, PITX2, NFKBIZ, SATB2, ARID5A, PKN1, RB1, FOSB, HNF4G, FOXJ3, PURA, RBBP8, SLTM, MED7, VEGFA, SMARCAL1, GLI3, BBS7, TADA3, ZNF367, SOX7, ABCA2, FOXQ1, LYL1, JUND, CHD1, SUPT4H1, NFATC3, TFDP1, MAFG, SREBF1, KAT2A, MAF, BRD3, TBX3, MAFB, ZMYM6, CREB1, TFCP2, ECM1, ZBED1, ATF3, RFX1, MAFA, RFX2 |
| GO:0060213 positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 2.20E-05   | 7     | ZFP36, TNRC6C, BTG2, CPEB3, CNOT1, CNOT7, TNRC6B                                                   |
| GO:0007155 cell adhesion                                                  | 7.30E-04   | 48    | ITGAL, SPG7, CCL2, SCN1B, NINJ2, ITGB5, CLDN10, POSTN, PCDHG3, NEO1, CD151, PCDHAC2, SCARF1, VCL, APLP1, VCAM1, CD47, LPXN, WISP2, LAMB3, COL6A6, SORB2, COL12A1, LAMB1, COL8A1, SPON1, DSCAM, ICAM1, SVEP1, ICAM4, PTPRF, ICAM3, ITGA2, CCL4L1, IFGALS, PCDH17, TPBG, SIRPA, COL4A6, ARVCF, CDH13, PRKD2, SIGLEC5, CD34, CX3CR1, NPHS1, DSC2, CFDP1 |
| GO:1900153 positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 0.001235   | 6     | ZFP36, TNRC6C, CPEB3, CNOT1, CNOT7, TNRC6B                                                    |
| GO:0034097 response to cytokine                                          | 0.00135    | 11    | FNTB, FOS, IFI27, REL, JUN, JUND, ITIH4, PML, RARA, BCL2L1, FOSL1                              |
| GO:0030198 extracellular matrix organization                             | 0.001421   | 25    | ITGAL, PDGFB, LUM, ADAMTS4, ITGB5, POSTN, VCAM1, CD47, LAMB3, POMT1, SERPINE1, BCL3, AGRN, LAMB1, COL8A1, VWA1, COL4A4, ICAM1, ICAM4, ICAM3, OLFML2A, ITGA2, NID1, COL4A6, EGFLAM |
| GO:0007165 signal transduction                                          | 0.001834   | 99    | IL9R, TNFSF15, TNFSF14, IL15, CNOT7, CD2AP, ADORA1, UNC5B, CHRRA9, ILRA2, MIER1, PPP1R1B, PDE4B, RARA, CCL4L1, GEM, IL21, TANK, VEGFC, ARR31, CD34, CSNK1G3, EXT2, ITGAL, CCL2, SP110, MDK, GPR27, TEK, AGRN, NPHP1, MAP2K3, SMAD5, MRC2, SPHK1, NR4A2, NR4A1, ECM1, TRADD, ZNF217, PLCG1, PDE7A, IL5RA, GRB7, PLAU, PDI3, HINT1, RASSF9, KCNK10, ARHGAP12, LNPEP, WISP2, MKLN1, NR2F6, SHC1, CASP1, LTB, IFNGR1, IRAK1, AVP, ARHGAP28, IFGALS, PKN1, ARRD3, PRKCD, OR51G2, DAPK1, CD83, TNFRSF10B, TNFRSF10D, ZDHHC13, RIN2, MAP3K10, GN5B, NRG1, RASD1, SRFAP2, THOC1, PRKCD, |
Table 2 The top 15 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of DEGs.

| Pathway Description                                                                 | Score  | DEGs                                                                 |
|-----------------------------------------------------------------------------------|--------|----------------------------------------------------------------------|
| GO:0044344 cellular response to fibroblast growth factor stimulus                  | 0.002221 | ZFP36, HYAL1, EGR3, CCL2, NR4A1, POSTN, KDM5B, GCLM                  |
| GO:0016477 cell migration                                                          | 0.002833 | PRKCZ, ARC, FGFR4, FMNL3, CCDC88A, PTPRF, CD151, MDK, SDC2, PDPK1, SDC1, PLCG1, HOXA5, SORBS2, GSK3B, ARPC5L, SH3KBP1, TGFRBR3, TNN, CSK, USP33, SPATA13 |
| GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling              | 0.002881 | IRAK1, SECTM1, F2RL1, TRIM13, PARK2, PIM2, ECM1, TRADD, TRAF3IP2, CASP10, CTH, TNFRSF10B, REL, MIER1, ZDHHC13, TICAM2, TGM2, PELI2, CASP1, IL1A, F2R |
| GO:0042493 response to drug                                                        | 0.003154 | XP01, SORD, ABCA2, PPOX, GCLM, MDK, HADHA, B2M, FOS, GAD2, JUND, PEMT, DHODH, CCNO, DNMT3B, FOSL1, SREBF1, ICAM1, SLC8A1, CREB1, ANXA1, ITGA2, DPYSL2, FOSB, CPT1A, SS18, VEGFC, JUN, ABCC4, ABCC1, IGFBP2, HTR2A, ABCC6 |
| GO:0014070 response to organic cyclic compound                                      | 0.003223 | KAT2A, FNTB, ICAM1, CD83, G6PD, BTG2, LUM, ABCC4, CPT1A, POLR2A      |
| GO:0009612 response to mechanical stimulus                                          | 0.003595 | CCL2, PTGER4, BTG2, JUN, JUND, POSTN, FOSB, IGFBP2, MBD2, PSPH, FOSL1 |
| GO:0050927 positive regulation of positive chemotaxis                              | 0.003653 | CDH13, VEGFA, F2RL1, ITGA2, F7                                       |
| GO:0008285 negative regulation of cell proliferation                               | 0.003913 | RARRES1, PML, SOX4, SOX7, MX11, CNOT7, ADORA1, KANK2, LIF, FNTB, CCL3L1, CCL3L3, PEMT, RARA, AXIN2, CSK, FOSL1, IL1A, CTBP1, DAB2IP, NACC2, PDS5B, CGRRF1, JARID2, VHL, KLF10, RB1, PIM2, FRZB, SLIT3, CDH13, TNFRSF9, VEGFC, BTG2, JUN, SCIN, GDF11, RBM38, MDM4, F2R |
| Description                                           | P Value   | Count | Gene Symbol                                                                 |
|-------------------------------------------------------|-----------|-------|-----------------------------------------------------------------------------|
| hsa05323 Rheumatoid arthritis                         | 0.001819  | 15    | TCIRG1, ICAM1, ITGAL, CCL3, CCL2, IL15, ATP6V1C1, FOS, CCL3L1, JUN, TEK, VEGFA, CCL3L3, LTB, IL1A |
| hsa02010 ABC transporters                             | 0.002041  | 10    | ABCB8, TAP1, ABCC4, ABCC1, ABCA2, ABCB6, ABCA6, ABCG1, ABCC5, ABCC6        |
| hsa04668 TNF signaling pathway                        | 0.004494  | 16    | ICAM1, CCL2, SOCS3, MAP2K3, CREB1, CREB5, MAPK11, IL15, TRADD, VCAM1, RPS6KA5, LIF, CASP10, FOS, JUN, BCL3 |
| hsa04130 SNARE interactions in vesicular transport    | 0.006102  | 8     | STX6, STX3, BET1, SEC22B, VAMP4, VAMP3, VAMP1, STX1B                        |
| hsa05166 HTLV-I infection                             | 0.009722  | 28    | ITGAL, XPO1, PDGFB, PPP3R2, ANAPC11, IL15, BCL2L1, VCA1, FOS, POLE3, NFATC3, FOSL1, TBPL1, NFATC1, ZFP36, KAT2A, ICAM1, EGR2, ANAPC5, CREB1, ANAPC4, CDC23, RB1, CDC27, ATF3, CCND2, JUN, GSK3B |
| hsa04120 Ubiquitin mediated proteolysis               | 0.018961  | 17    | ANAPC5, SOCS3, VHL, ANAPC4, PML, CDC23, KEAP1, ANAPC11, PARK2, UBE2Q2, CDC27, PRPF19, WWP2, UBA3, SIAH1, PIAS2, CUL4B |
| hsa05132 Salmonella infection                         | 0.020675  | 12    | FOS, CCL3, CCL3L1, JUN, ARPC5L, CCL3L3, PKN1, CCL4L1, MAPK11, CASP1, IL1A, IFNGR1 |
| hsa04514 Cell adhesion molecules (CAMs)                | 0.025698  | 17    | ICAM1, ITGAL, PTPRF, VTCN1, ICAM3, CD276, NTNG1, NTNG2, CLDN10, NEO1, CLDN11, SDC2, CLDN15, VCA1, SDC1, CD34, ICOS |
| hsa04380 Osteoclast differentiation                   | 0.026566  | 16    | FOSL2, SOCS3, CREB1, PPP3R2, MAPK11, FOSB, SIRPA, FOS, LILRA2, JUN, JUND, FOSL1, IFNGR1, IL1A, SYK, NFATC1 |
| hsa04064 NF-kappa B signaling pathway                  | 0.028321  | 12    | VCAM1, ICAM1, IRAK1, PLCG1, TICAM2, CCL4L1, TNFSF14, BCL2L1, LTB, PLAU, TRADD, SYK |
| hsa04151 PI3K-Akt signaling pathway                    | 0.050168  | 32    | FGFR4, PDGFB, ITGB5, BCL2L1, FOXO3, PDPK1, LAMB3, COL6A6, TEK, GYS1, TNN, LAMB1, PPP2R2B, SYK, PPP2R1B, COL4A4, SGK1, CREB1, NR4A1, ITGA2, PKN1, CREB5, COL4A6, VEGFC, CCND2, GSK3B, VEGFA, GNB5, EFNA5, THEM4, PPP2R3C, F2R |
| hsa04512 ECM-receptor interaction                     | 0.061638  | 11    | COL4A4, CD47, LAMB3, SDC1, COL6A6, ITGB5, ITGA2, TNN, AGRN, LAMB1, COL4A6 |
| hsa04152 AMPK signaling                               | 0.063824  | 14    | PPP2R1B, SREBF1, CPT1C, SCD, CREB1, ACACA, CREB5, FOXO3, CPT1A, PD PK1, GYS1, PPP2R2B, RAB10, |
### Table 3 The most significant biological process enriched for the genes involved in six modules.

| Description                                           | P Value | Count | Gene Symbol                                                                 | Module |
|-------------------------------------------------------|---------|-------|----------------------------------------------------------------------------|--------|
| GO:0045842 positive regulation of mitotic metaphase/anaphase transition | 0.00    | 5     | ANAPC11, ANAPC4, ANAPC5, CDC23, CDC27                                       | Module 1|
| GO:0048284 organelle fusion                           | 0.00    | 15    | ANXA1, BET1, CPLX2, PRKN, RAB20, RAB8B, SEC22B, STX1B, STX3, STX6, SYT9, TFRC, VAMP1, VAMP3, VAMP4 | Module 3|
| GO:0003093 regulation of glomerular filtration        | 0.00    | 4     | ADORA1, F2R, F2RL1, PDGFB                                                   | Module 3|
| GO:0071426 ribonucleoprotein complex export from nucleus | 0.00    | 10    | AGFG1, MAGOHB, NUP153, NUP155, RAE1, RIK2, SRRM1, THOC1, WDR33, XPO1       | Module 4|
| GO:0033627 cell adhesion mediated by integrin         | 0.00    | 8     | ICAM1, ITGA2, ITGB5, LPXN, PLAU, PLPP3, SERPINE1, SYK                       | Module 5|
| GO:0030490 maturation small subunit ribosomal RNA (SSU-rRNA) | 0.00    | 6     | HEATR1, KRI1, NOL11, RIK2, SRFBP1, WDR3                                     | Module 5|
| GO:0009051 pentose-phosphate shunt, oxidative branch | 0.00    | 4     | G6PD, PGD, PHGDH, UBL4A                                                     | Module 6|

### Table 4 The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched for genes involved in 6 modules.

| Pathway                                                                 | P Value | Count | Gene Symbol                                                                 |
|------------------------------------------------------------------------|---------|-------|----------------------------------------------------------------------------|
| hsa05031 Amphetamine addiction                                         | 0.06951 | 9     | FOS, ARC, PPP1R1B, JUN, CAMK2G, CREB1, PPP3R2, CREB5, FOSB                  |
| hsa05142 Chagas disease (American trypanosomiasis)                     | 0.083357| 12    | PPP2R1B, IRAK1, FOS, CCL3, CCL2, CCL3L1, JUN, CCL3L3, SERPINE1, MAPK11, PPP2R2B, IFNGR1 |
| Description                                                                 | P Value | Count | Gene Symbol                                                                 | Module |
|----------------------------------------------------------------------------|---------|-------|----------------------------------------------------------------------------|--------|
| KEGG:04120 ubiquitin mediated proteolysis                                   | 0.00    | 15    | ANAPC11, ANAPC4, ANAPC5, CDC23, CDC27, CUL4B, KEAP1, PML, PRKN, PRPF19, SIAH1, SOCS3, UBA3, UBE2Q2, VHL | 1      |
| KEGG:04130 soluble NSF Attachment Protein Receptor (SNARE) interactions in vesicular transport | 0.00    | 8     | BET1, SEC22B, STX1B, STX3, STX6, VAMP1, VAMP3, VAMP4                      | 3      |
| KEGG:04512 extracellular matrix (ECM)-receptor interaction                 | 0.00    | 8     | CD47, COL4A4, COL4A6, COL6A6, ITGA2, ITGB5, LAMB1, SDC1                  | 4      |

Table 5 The top 30 hub genes rank in cytoHubba.
| Betweenness | Bottleneck | Eccentricity | EPC | MNC |
|------------|-----------|-------------|-----|-----|
| ALB        | ALB       | NACC2       | ALB | ALB |
| VEGFA      | VEGFA     | JUN         | JUN | JUN |
| JUN        | EPRS      | POLR2A      | VEGFA | VEGFA |
| EPRS       | FOS       | ANAPC4      | FOS | FOS |
| POLR2A     | JUN       | RPL10       | SOCS3 | POLR2A |
| ALDH18A1   | ALDH18A1  | CDC27       | CCL2 | HIST2H2BE |
| GSK3B      | GSK3B     | FOS         | ICAM1 | CREB1 |
| CREB1      | CREB1     | RPSA        | CREB1 | CCL2 |
| FOS        | RB1       | PLCG1       | KEAP1 | ICAM1 |
| RAB11A     | VCL       | RB1         | POLR2A | EPRS |
| TFRC       | BCL2L1    | CASP2       | VCAM1 | SOCS3 |
| BCL2L1     | RAB11A    | AXIN2       | PARK2 | POLR2L |
| VCL        | LMNA      | G6PD        | HIST2H2BE | TFRC |
| RB1        | CD34      | PPP2R1B     | VHL | B2M |
| HIST2H2BE  | SLC35A2   | HIST2H2BE   | BCL2L1 | RAB11A |
| B2M        | POSTN     | VEGFA       | GSK3B | KEAP1 |
| RPSA       | SREBF1    | CCND2       | B2M | BCL2L1 |
| SOCS3      | GAD2      | CD34        | CDC27 | HIST1H2BN |
| G6PD       | G6PD      | SMARCD3     | SHC1 | VCAM1 |
| KEAP1      | IRAK1     | XPO1        | SIAH1 | RPSA |
| ARRB1      | RTN4      | MAPK11      | CDC23 | CDC27 |
| CTTN       | CCL2      | DPYSL2      | TFRC | GSK3B |
| CCL2       | CYFIP1    | RTN4        | FBXL19 | SHC1 |
| EIF4G1     | SPHK1     | NR4A2       | ANAPC11 | ARRB1 |
| SREBF1     | KEAP1     | KDM1A       | CD34 | PARK2 |
| CD34       | PSMA4     | HIST1H2BN   | FBXL5 | VHL |
| XPO1       | CTTN      | CASP1       | KCTD6 | RPLP0 |
| RPLP0      | CCND2     | EPRS        | ASB6 | CTTN |
Table 6 More Information of The Hub genes.

| Gene  | Function                                                                                                                                                                                                 | Authors                                      | PMID          |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|---------------|
| VEGFA | Activates VEGFR2 and promotes endothelial proliferation, migration and survival as well as vascular hyperpermeability                                                                                     | Katsuyuki Tanabe, Jun Wada, Yasufumi Sato     | 32144398      |
| JUN and FOS | AP-1 up-regulate proinflammatory and profibrogenic genes  
AP-1 transcription activity is associated with fibrosis                                                                                       | S.A. Mezzano, M.Barria, M.A. Droguett, Z. Yang, F. Xiong, Y. Wang | 11576350, 27317945 |

Table 7 Gene sets enriched in phenotype high.

| Name                     | ES       | NES        | NOM p-val   | FDR q-val |
|--------------------------|----------|------------|-------------|-----------|
| HALLMARK_ANGIOGENESIS    | 0.4953875| 1.7208529  | 0.012320329 | 0.1586698 |

FDR: false discovery rate; NES: normalized enrichment score; NOM: nominal. Gene sets with NOM P-val <0.05 and FDR q-val <0.25 are considered as significant.

Figures
**Figure 1**

Identification of DEGs Volcano plot of DEGs in IMN. The cut-off criteria were $|\log 2 Fc|>1$ and $P$ value $<0.05$. The red dots represented the up-regulated genes, and the blue dots denoted the down-regulated genes. The grey dots indicated the genes with a $|\log 2 Fc|<1$ and/or $P$ value $>0.05$. 
Figure 2

The heat map of the top 50 up-regulated genes and the top 50 down-regulated genes, gray indicates a relatively low expression and red indicates a relatively high expression.
Figure 3

Gene Ontology (GO) and KEGG enrichment analysis of DEGs. GO enrichment analysis of DEGs showed (a) biological process (BP); (b) cellular component (CC); (c) molecular function (MF); and (d) KEGG enrichment analysis of DEGs.
Figure 4

6 modules identified by MCODE 6 modules from the PPI network were selected. The red nodes represented the up-regulated genes, the green nodes represented the down-regulated genes: (a) module 1; (b) module 2; (c) module 3; (d) module 4; (e) module 5; (f) module 6.
Figure 5

Biological process enrichment analysis of modules genes.
**Figure 6**

Cellular component enrichment analysis of modules genes.

**Figure 7**

Molecular function enrichment analysis of modules genes.

**Figure 8**

Module interactions and regional functions analysis of modules genes.
Figure 9

Hub genes identified by different methods. The hub genes in PPI network screened out via intersected by Betweenness, Bottleneck, Eccentricity, EPC, and MNC method.
Figure 10

Signaling pathway activated in kidney biopsies from IMN patients.
Figure 11

Expression profile of core genes involved in angiogenesis in GSE115857. The red nodes represent up-regulated DEGs with a p-value of <0.05 and logFC >1.0; the green nodes represent down-regulated DEGs with a p-value of <0.05 and logFC <-1.0.
Figure 12

The possible mechanisms by which VEGFA/PI3K/Akt is involved in IMN.